These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 34207884)

  • 21. Preclinical Chimeric Antibody Chimeric Antigen Receptor T Cell Progress in Digestive System Cancers.
    Lü P; Qiu S; Pan Y; Yu F; Chen K
    Cancer Biother Radiopharm; 2021 May; 36(4):307-315. PubMed ID: 33481647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy.
    Grywalska E; Sosnowska-Pasiarska B; Smok-Kalwat J; Pasiarski M; Niedźwiedzka-Rystwej P; Roliński J
    Cells; 2020 Apr; 9(4):. PubMed ID: 32316105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Chimeric Antigen Receptor-T Cell Therapy in the Treatment of Hematological Malignancies: Advantages, Trials, and Tribulations, and the Road Ahead.
    Rohit Reddy S; Llukmani A; Hashim A; Haddad DR; Patel DS; Ahmad F; Abu Sneineh M; Gordon DK
    Cureus; 2021 Feb; 13(2):e13552. PubMed ID: 33815972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
    Yu YD; Kim TJ
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
    Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
    Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospects and challenges for use of CAR T cell therapies in solid tumors.
    Ramakrishna S; Barsan V; Mackall C
    Expert Opin Biol Ther; 2020 May; 20(5):503-516. PubMed ID: 32125191
    [No Abstract]   [Full Text] [Related]  

  • 28. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
    Siegler EL; Wang P
    Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of response and resistance to CAR T cell therapy.
    Lesch S; Benmebarek MR; Cadilha BL; Stoiber S; Subklewe M; Endres S; Kobold S
    Semin Cancer Biol; 2020 Oct; 65():80-90. PubMed ID: 31705998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives.
    Lee YH; Kim CH
    Arch Pharm Res; 2019 Jul; 42(7):607-616. PubMed ID: 30830661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
    Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
    Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
    Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
    Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
    J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
    Fu M; Tang L
    Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [CAR-T Immunotherapy and Non-small Cell Lung Cancer: Bottleneck and Dawn].
    Zhang L; Li H; Zhang F; Wang S; Li G
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):916-920. PubMed ID: 32810975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy.
    Cortés-Selva D; Dasgupta B; Singh S; Grewal IS
    Trends Pharmacol Sci; 2021 Jan; 42(1):45-59. PubMed ID: 33250273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.